Venetoclax combined with three-day multi-frequency decitabine (DEC3-VEN) in elder or intensive chemotherapy ineligible patients with newly diagnosed acute myeloid leukemia
Year: 2024
Type: article
Abstract: In recent years, Venetoclax (Ven) has gained a prominent position in the treatment of newly diagnosed acute myeloid leukemia (AML) patients. Combinations of Ven with hypomethylating agents (HMA), Azacitidine (AZA) or decitabine (DEC), have become the first-line treatment for newly diagnosed AML patients who are elderly or not suitable for intensive chemotherapy (IC), with CR rates around 60–70% [ 1 , 2 , 3 ]. Other studies have demonstrated that ten-day DEC combined with Ven can significantly improve the CR rate in newly diagnosed AML patients, albeit at the cost of a notably prolonged bone marrow suppression period [ 4 ]. The optimal method of combining Ven with HMA remains an area of ongoing investigation.
Source: Blood Cancer Journal
Authors: Xiaohui Suo, Xiaojun Ma, Fang Zheng, Dongmei Wang, Guanchen Bai, Liyun Zhao, Zhongjing Han, Xin Lv, Congcong Zhang, Ju Wang, Kangxin Tuo, Zhen Meng, Shan Liu, Sifeng Gao, Jilei Zhang, Zongjiu Jiao, Jiaojie Song, Ling Li, Xinxiao Lu, Linyu Yuan, Kaiqi Liu, Xingli Zhao, Yingchang Mi
Institutions: Harrison International Peace Hospital, Qingdao University, Taian City Central Hospital, Xingtai People's Hospital, Daqing Oilfield General Hospital, Linyi People's Hospital, Inner Mongolia People's Hospital, Tianjin People's Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Institute of Hematology & Blood Diseases Hospital, State Key Laboratory of Experimental Hematology
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $4,990
Awards: G2961488978, G6061092259
OpenAlex ID: W4404548388